September 17, 2024 07:18 AM EDTUpdated 11:37 AM

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Kyle LaHucik

Senior Reporter

BARCELONA — Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last year’s European …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

Edgewise’s stock surges as heart drug passes early safety test

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Breaking down silos with a new quantitative approach to drug development

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers